| P50 | author | Harrys A Torres | Q56850563 |
| P2093 | author name string | Ahmed Kaseb | |
| | Felipe Samaniego | |
| | Vincent Mallet | |
| | Nassim Hammoudi | |
| | Terri Lynn Shigle | |
| | James T Link | |
| P2860 | cites work | Eradication of Hepatitis C Virus Infection and the Development of Hepatocellular Carcinoma | Q22305316 |
| | Hepatic decompensation is the major driver of death in HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma. | Q40335094 |
| | Increased peripheral CD4+ regulatory T cells persist after successful direct-acting antiviral treatment of chronic hepatitis C. | Q40389307 |
| | Late Relapse Versus Hepatitis C Virus Reinfection in Patients With Sustained Virologic Response After Sofosbuvir-Based Therapies. | Q40466129 |
| | Influence of Successful Chronic Hepatitis C Virus Treatment with Ledipasvir/Sofosbuvir on Warfarin Dosing Requirements in Four Veterans. | Q40466282 |
| | Concomitant use of direct-acting antivirals and chemotherapy in hepatitis C virus-infected patients with cancer | Q40487793 |
| | Ombitasvir-Paritaprevir-Ritonavir-Dasabuvir (Viekira Pak)-Induced Lactic Acidosis | Q40529498 |
| | Transdisciplinary Approach to Managing Hepatitis C Virus Infection in Patients at a Tertiary Care Cancer Center. | Q40554171 |
| | Hepatocellular Carcinoma and Viral Hepatitis in New York City | Q40554744 |
| | Antiviral therapy improves overall survival in hepatitis C virus-infected patients who develop diffuse large B-cell lymphoma. | Q40584442 |
| | Evaluation of a Potential Interaction Between New Regimens to Treat Hepatitis C and Warfarin. | Q40597366 |
| | How I treat hepatitis C virus infection in patients with hematologic malignancies. | Q40604797 |
| | Severe hepatitis C reactivation as an early complication of hematopoietic cell transplantation | Q40610203 |
| | Hepatitis due to Reactivation of Hepatitis B Virus in Endemic Areas Among Patients With Hepatitis C Treated With Direct-acting Antiviral Agents | Q40620558 |
| | Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis | Q40621775 |
| | Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals | Q40634884 |
| | Development of non-Hodgkin lymphoma as a second primary cancer in hepatitis C virus-infected patients with a different primary malignancy. | Q40635319 |
| | The relationship between liver stiffness measurement and outcome in patients with chronic hepatitis C and cirrhosis: a retrospective longitudinal hospital study | Q40654311 |
| | Association Between Hepatitis C Virus and Head and Neck Cancers | Q40715941 |
| | Whole-genome mutational landscape and characterization of noncoding and structural mutations in liver cancer. | Q40720624 |
| | Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis | Q40811284 |
| | Lactic acidosis in patients with hepatitis C virus cirrhosis and combined ribavirin/sofosbuvir treatment | Q40874424 |
| | Increased incidence of cancer and cancer-related mortality among persons with chronic hepatitis C infection, 2006-2010. | Q40981955 |
| | Liver toxicity associated with sofosbuvir, an NS5A inhibitor and ribavirin use. | Q41022298 |
| | Cost-effectiveness of novel regimens for the treatment of hepatitis C virus | Q41211125 |
| | Effect of hepatitis C virus infection in patients with cancer: addressing a neglected population. | Q41547422 |
| | Fibrosing cholestatic hepatitis C after hematopoietic cell transplantation: report of 3 fatal cases | Q41594467 |
| | Life expectancy in patients with chronic HCV infection and cirrhosis compared with a general population | Q41667779 |
| | Coadministration of telaprevir and transcatheter arterial chemoembolization in hepatitis C virus-associated hepatocellular carcinoma | Q42101421 |
| | Toward a more complete understanding of the association between a hepatitis C sustained viral response and cause-specific outcomes | Q42159672 |
| | Hepatitis B and C seroprevalence in solid tumors - necessity for screening during chemotherapy | Q42233082 |
| | Does chemotherapy cause viral relapse in cancer patients with hepatitis C infection successfully treated with antivirals? | Q42241313 |
| | Evaluation of liver disease progression in the German hepatitis C virus (1b)-contaminated anti-D cohort at 35 years after infection | Q42277946 |
| | Prevalence of hepatitis C virus infection in patients with lymphoproliferative disorders | Q42977087 |
| | Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a case-control study. | Q42977618 |
| | Regression of an HCV-associated disseminated marginal zone lymphoma under IFN-free antiviral treatment. | Q42977842 |
| | Hepatitis C virus genotype distribution varies by underlying disease status among patients in the same geographic region: a retrospective multicenter study. | Q42978856 |
| | Acute exacerbation and reactivation of chronic hepatitis C virus infection in cancer patients. | Q42983064 |
| | Impact of hepatitis C virus infection on clinical outcome in recipients after allogeneic hematopoietic cell transplantation. | Q42990029 |
| | Hepatitis B or C viral infection and risk of pancreatic cancer: A meta-analysis of observational studies | Q22305489 |
| | The DNA damage sensors ataxia-telangiectasia mutated kinase and checkpoint kinase 2 are required for hepatitis C virus RNA replication | Q24318659 |
| | Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19·2 million participants | Q26749640 |
| | Hepatitis C virus and non-Hodgkin's lymphomas: Meta-analysis of epidemiology data and therapy options | Q26775007 |
| | Hepatitis C-associated B-cell non-Hodgkin lymphomas. Epidemiology, molecular signature and clinical management | Q27001012 |
| | Global epidemiology and genotype distribution of the hepatitis C virus infection | Q27001240 |
| | Improving the Diagnosis of Acute Hepatitis C Virus Infection with Expanded Viral Load Criteria | Q27489594 |
| | GRADE: an emerging consensus on rating quality of evidence and strength of recommendations | Q27860753 |
| | Hepatitis C | Q28084654 |
| | Hepatocellular carcinoma in cirrhosis: incidence and risk factors | Q28290048 |
| | Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to HCV seroprevalence | Q29616009 |
| | Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein | Q29620682 |
| | The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice | Q29620765 |
| | Impact of sustained viral response postcurative therapy of hepatitis C-related hepatocellular carcinoma: a systematic review and meta-analysis | Q30241048 |
| | APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing. | Q30250088 |
| | Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015. | Q30353189 |
| | A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt | Q30403548 |
| | Annual Report to the Nation on the Status of Cancer, 1975-2012, featuring the increasing incidence of liver cancer | Q30746254 |
| | Hepatitis viruses infection and risk of intrahepatic cholangiocarcinoma: evidence from a meta-analysis | Q31073665 |
| | Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: Data from three ANRS cohorts | Q31107310 |
| | Hepatitis C virus screening in patients with cancer receiving chemotherapy | Q33600085 |
| | Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune-suppressing and anticancer drugs: just the tip of the iceberg? | Q33872389 |
| | Liver biopsy | Q33932981 |
| | Intrahepatic cholangiocarcinoma and hepatitis C and B virus infection, alcohol intake, and hepatolithiasis: a case-control study in Italy | Q33957032 |
| | Hepatobiliary complications of hematopoietic cell transplantation, 40 years on. | Q34036696 |
| | Stem cell divisions, somatic mutations, cancer etiology, and cancer prevention | Q34048056 |
| | Hepatitis B and C virus, Clonorchis sinensis for the risk of liver cancer: a case-control study in Pusan, Korea | Q34063702 |
| | Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. | Q34294185 |
| | Review article: prescribing medications in patients with cirrhosis – a practical guide | Q34342554 |
| | Estimating progression to cirrhosis in chronic hepatitis C virus infection. | Q34389608 |
| | Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. | Q34390093 |
| | Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies | Q34468844 |
| | Toward a more accurate estimate of the prevalence of hepatitis C in the United States | Q34484872 |
| | Drug-related hepatotoxicity | Q34495071 |
| | The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013 | Q34533596 |
| | Hepatocellular mitochondrial alterations in patients with chronic hepatitis C: ultrastructural and biochemical findings | Q42994660 |
| | Past excessive alcohol consumption: a major determinant of severe liver disease among newly referred hepatitis C virus infected patients in hepatology reference centers, France, 2001. | Q42994668 |
| | Hepatitis C virus core protein inhibits mitochondrial electron transport and increases reactive oxygen species (ROS) production | Q42995051 |
| | Remission of Follicular Lymphoma after Treatment for Hepatitis C Virus Infection | Q42998885 |
| | Detection of hepatitis C virus RNA in oral lichen planus and oral cancer tissues | Q42999307 |
| | Hepatitis C virus and risk of lymphoma and other lymphoid neoplasms: a meta-analysis of epidemiologic studies | Q43033839 |
| | The B-cell receptor of a hepatitis C virus (HCV)–associated non-Hodgkin lymphoma binds the viral E2 envelope protein, implicating HCV in lymphomagenesis | Q43035602 |
| | Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection | Q43038794 |
| | HCV-associated liver cancer without cirrhosis | Q43040118 |
| | Hepatitis C virus infection in patients with non-Hodgkin's lymphoma | Q43040331 |
| | Hepatocellular carcinoma as a second primary cancer in patients with chronic hepatitis C virus infection. | Q43041927 |
| | Thalidomide with peginterferon alfa-2b and ribavirin in the treatment of non-responders genotype 1 chronic hepatitis C patients: proof of concept | Q43047008 |
| | Inhibition of warfarin activity by ribavirin | Q43869933 |
| | Clinical outcomes after transfusion-associated hepatitis C. | Q44746801 |
| | Management and treatment of hepatitis C virus infection in HIV-infected adults: recommendations from the Veterans Affairs Hepatitis C Resource Center Program and National Hepatitis C Program Office | Q45332996 |
| | Quantifying the fraction of cirrhosis attributable to alcohol among chronic hepatitis C virus patients: implications for treatment cost-effectiveness. | Q45354911 |
| | Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study | Q45356128 |
| | Hepatitis C virus infection and bone marrow transplantation: a cohort study with 10-year follow-up | Q45749242 |
| | Fulminant hepatitis on withdrawal of chemotherapy in carriers of hepatitis C virus | Q45772528 |
| | Prevalence of antibodies to hepatitis C virus in Italian patients with hepatocellular carcinoma | Q45844527 |
| | Prevalence of antibodies to hepatitis C virus in Spanish patients with hepatocellular carcinoma and hepatic cirrhosis | Q45844531 |
| | Interaction of ribavirin with azathioprine metabolism potentially induces myelosuppression. | Q46461224 |
| | Clinicopathological study on cholangiolocellular carcinoma suggesting hepatic progenitor cell origin | Q46661060 |
| | Transporters in Drug Development and Clinical Pharmacology | Q46880795 |
| | Hepatitis C: Down but Not Out. | Q47849645 |
| | Paritaprevir/ritonavir/ombitasvir+dasabuvir plus ribavirin therapy and inhibition of the anticoagulant effect of warfarin: a case report. | Q47999149 |
| | Editorial: the burden of chronic liver disease - an ecological method sees the wood for the trees | Q48130564 |
| | Inhibition of eIF4E with ribavirin cooperates with common chemotherapies in primary acute myeloid leukemia specimens | Q50556822 |
| | Treatment of chronic hepatitis C in non-responsive patients with pegylated interferon associated with ribavirin and thalidomide: report of six cases of total remission | Q50576318 |
| | Prognosis of chronic hepatitis C: results of a large, prospective cohort study | Q50856021 |
| | Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis | Q53118691 |
| | Telomerase reverse transcriptase promoter mutation is an early somatic genetic alteration in the transformation of premalignant nodules in hepatocellular carcinoma on cirrhosis. | Q53232555 |
| | Direct acting antiviral therapy and tumor recurrence after liver transplantation for hepatitis C-associated hepatocellular carcinoma | Q54505335 |
| | Hepatocellular carcinoma recurrence after treatment with direct-acting antivirals: First, do no harm by withdrawing treatment. | Q54583963 |
| | Expanding consensus in portal hypertension | Q58034372 |
| | Long-term outcome of hepatitis C infection after bone marrow transplantation | Q58034510 |
| | Direct acting antivirals for decompensated cirrhosis. Efficacy and safety are now established | Q87415954 |
| | Evaluation for liver transplantation in adults: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation | Q87644212 |
| | Unexpected high incidence of hepatocellular carcinoma in cirrhotic patients with sustained virologic response following interferon-free direct-acting antiviral treatment | Q87700511 |
| | EASL Recommendations on Treatment of Hepatitis C 2016 | Q88412279 |
| | Risk of hepatobiliary and pancreatic cancers after hepatitis C virus infection: A population-based study of U.S. veterans | Q37286554 |
| | Hepatitis C and non-Hodgkin lymphoma among 4784 cases and 6269 controls from the International Lymphoma Epidemiology Consortium | Q37656186 |
| | Hepatitis C and Non-Hodgkin Lymphoma: The Clinical Perspective | Q37961614 |
| | Reactivation of hepatitis B virus and hepatitis C virus in patients with cancer | Q37978202 |
| | Hepatitis C virus infection and the risk of cancer among elderly US adults: A registry-based case-control study. | Q38403156 |
| | Hepatitis C Virus Infection among Hematopoietic Cell Transplant Donors and Recipients: American Society for Blood and Marrow Transplantation Task Force Recommendations | Q38563497 |
| | Impact of natural killer cells on chronic hepatitis C and hepatocellular carcinoma | Q38635000 |
| | Interferon-free antiviral treatment in B-cell lymphoproliferative disorders associated with hepatitis C virus infection. | Q38878808 |
| | Evaluation of hepatitis B reactivation among 62,920 veterans treated with oral hepatitis C antivirals | Q38939913 |
| | Management of viral hepatitis in patients with haematological malignancy and in patients undergoing haemopoietic stem cell transplantation: recommendations of the 5th European Conference on Infections in Leukaemia (ECIL-5). | Q38947451 |
| | Management of the patient with SVR. | Q38958185 |
| | Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort | Q38965567 |
| | Genetic basis of hepatitis virus-associated hepatocellular carcinoma: linkage between infection, inflammation, and tumorigenesis | Q38974653 |
| | The impact of direct antiviral agents on the development and recurrence of hepatocellular carcinoma. | Q39067301 |
| | Thalidomide in the treatment of chronic hepatitis C unresponsive to alfa-interferon and ribavirin | Q39250831 |
| | Geographical variations in incidence, management and survival of hepatocellular carcinoma in a Western country | Q39257247 |
| | Estimating the burden of disease attributable to injecting drug use as a risk factor for HIV, hepatitis C, and hepatitis B: findings from the Global Burden of Disease Study 2013. | Q39354156 |
| | Global burden of cancers attributable to infections in 2012: a synthetic analysis. | Q39360739 |
| | Liver-related mortality in countries of the developed world: an ecological study approach to explain the variability. | Q39758401 |
| | Alcohol intake increases the risk of HCC in hepatitis C virus-related compensated cirrhosis: A prospective study | Q39765011 |
| | Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy | Q39846654 |
| | Contribution of alcohol use disorders on the burden of chronic hepatitis C in France, 2008-2013: A nationwide retrospective cohort study | Q40249396 |
| | Increases in hepatitis C virus infection related to injection drug use among persons aged ≤30 years - Kentucky, Tennessee, Virginia, and West Virginia, 2006-2012. | Q40278327 |
| | Sinusoidal obstruction syndrome after allogeneic hematopoietic stem cell transplantation: Incidence, risk factors and outcomes. | Q40288619 |
| | Impact of Hepatitis C Virus Eradication on the Clinical Outcome of Patients with Hepatitis C Virus-Related Advanced Hepatocellular Carcinoma Treated with Sorafenib | Q40314564 |
| | Hepatitis B reactivation in patients with chronic hepatitis C undergoing anti-viral therapy with an interferon-free regimen | Q40333357 |
| | Epidemiology of cholangiocarcinoma: an update focusing on risk factors. | Q34615924 |
| | Association between hepatitis B or hepatitis C virus infection and risk of pancreatic adenocarcinoma development: a systematic review and meta-analysis. | Q34657129 |
| | Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure. | Q34735059 |
| | A 20-year prospective study of cirrhosis | Q34776653 |
| | Occult and previous hepatitis B virus infection are not associated with hepatocellular carcinoma in United States patients with chronic hepatitis C. | Q35100009 |
| | Prevalence of hepatitis C virus infection in B-cell non-Hodgkin's lymphoma: systematic review and meta-analysis. | Q35629704 |
| | Ribavirin Inhibits the Activity of mTOR/eIF4E, ERK/Mnk1/eIF4E Signaling Pathway and Synergizes with Tyrosine Kinase Inhibitor Imatinib to Impair Bcr-Abl Mediated Proliferation and Apoptosis in Ph+ Leukemia | Q35758763 |
| | Hepatitis B Virus Screening for Patients With Cancer Before Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update. | Q35771194 |
| | B-cell non-Hodgkin's lymphoma and hepatitis C virus infection: a systematic review | Q35797604 |
| | Reactivation of hepatitis C virus after chemotherapy for colon cancer | Q35801323 |
| | Possible association between hepatitis C virus and malignancies different from hepatocellular carcinoma: A systematic review. | Q35868937 |
| | Prevalence of hepatitis B and C and sensibility of a selective screening questionnaire in patients receiving chemotherapy for solid tumors. | Q35875680 |
| | Effect of hepatitis C virus infection on the risk of non-Hodgkin's lymphoma: a meta-analysis of epidemiological studies | Q35911859 |
| | Fulminant hepatitis B reactivation leading to liver transplantation in a patient with chronic hepatitis C treated with simeprevir and sofosbuvir: a case report | Q35949952 |
| | Awareness of infection, knowledge of hepatitis C, and medical follow-up among individuals testing positive for hepatitis C: National Health and Nutrition Examination Survey 2001–2008 | Q36100389 |
| | DAAs Rapidly Reduce Inflammation but Increase Serum VEGF Level: A Rationale for Tumor Risk during Anti-HCV Treatment | Q36229505 |
| | Hepatitis C virus has a genetically determined lymphotropism through co-receptor B7.2. | Q36244165 |
| | Viekira Pak (Ombitasvir, Paritaprevir, and Ritonavir Tablets; Dasabuvir Tablets): All-Oral Fixed Combination Approved for Genotype 1 Chronic Hepatitis C Infection | Q36333772 |
| | Hepatic expression of HCV RNA-dependent RNA polymerase triggers innate immune signaling and cytokine production | Q36354446 |
| | Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases | Q36464103 |
| | Bystander hyperactivation of preimmune CD8+ T cells in chronic HCV patients | Q36575593 |
| | Hepatitis B virus and hepatitis C virus play different prognostic roles in intrahepatic cholangiocarcinoma: A meta-analysis | Q36656633 |
| | Evaluation of the Centers for Disease Control and Prevention Recommendations for Hepatitis C Virus Testing in an Urban Emergency Department | Q36783216 |
| | Strategies for safer liver surgery and partial liver transplantation | Q36788914 |
| | Hepatitis C Virus Infection in Patients Undergoing Hematopoietic Cell Transplantation in the Era of Direct-Acting Antiviral Agents. | Q36790040 |
| | Commentary: Oncologic drugs in patients with organ dysfunction: a summary | Q36959585 |
| | Hematopoietic malignancies associated with viral and alcoholic hepatitis | Q37003041 |
| | Risk of hepatocellular carcinoma after sustained virological response in Veterans with hepatitis C virus infection | Q37029846 |
| | Determinants of esophageal varices bleeding in patients with advanced hepatocellular carcinoma treated with sorafenib. | Q37045749 |
| | CYP450 pharmacogenetics for personalizing cancer therapy | Q37166488 |
| | Liver fibrosis progression in hepatitis C virus infection after seroconversion | Q37244507 |
| | Are common factors involved in the pathogenesis of primary liver cancers? A meta-analysis of risk factors for intrahepatic cholangiocarcinoma | Q37246194 |
| | Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma | Q37284612 |
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | hepatitis C | Q154869 |
| | Hepatitis C virus | Q708693 |
| P304 | page(s) | 411-431 | |
| P577 | publication date | 2017-07-06 | |
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | CA | Q326141 |
| P1476 | title | The oncologic burden of hepatitis C virus infection: A clinical perspective | |
| P478 | volume | 67 | |